Jeffrey Chi - 12 Feb 2025 Form 3 Insider Report for Aardvark Therapeutics, Inc. (AARD)

Role
Director
Signature
/s/ Jeffrey Chi
Issuer symbol
AARD
Transactions as of
12 Feb 2025
Net transactions value
$0
Form type
3
Filing time
12 Feb 2025, 18:55:11 UTC
Next filing
19 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AARD Series C Convertible Preferred Stock 12 Feb 2025 Common Stock 133,364 By Vickers Venture Co-investment LLC F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") is convertible into shares of common stock of the Issuer ("Common Stock") at the holder's election on an 8.474-for-1 basis and has no expiration date. All shares of Series C Convertible Preferred Stock will automatically convert on an 8.474-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
F2 Vickers Venture Co-investment LLC ("Vickers Co-investment") is managed by Vickers Venture Partners (S) Pte. Ltd. which is in turn managed by its directors, being Dr. Jeffrey Chi and Dr. Finian Tan, who collectively exercise sole voting and dispositive power over the securities held by Vickers Co-investment. Each of Vickers Venture Partners (S) Pte. Ltd., Dr. Jeffrey Chi and Dr. Finian Tan disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.

Remarks:

Exhibit 24 - Power of Attorney